Health ❯ Healthcare

Clinical Trials

Drug Development Phase 3 Trials Drug Efficacy Patient Outcomes Phase III Trials Research Studies Randomized Controlled Trials Efficacy Studies Cancer Research Cancer Treatment

FDA Rejects Aldeyra’s Dry-Eye Drug Again After Finding Evidence Lacking

Regulators cited inadequate efficacy evidence.

India Poised for Semaglutide Generics as Patent Expires, Prices Expected to Plunge

Structure’s Oral Obesity Pill Delivers 16.3% Placebo-Adjusted Weight Loss in Phase 2

PrimeC Shows Safety and Potential Benefit in ALS Phase 2b as FDA Authorizes Phase 3

Stories older than 24h

Large Trial Finds No Acute COVID Benefit From Vitamin D, Hints at Fewer Long COVID Symptoms

Biomea Fusion Reports Positive 52-Week Phase II Results for Icovamenib in Diabetes

Blood Studies Point to Complementary Alzheimer’s Biomarkers for Prediction and Staging

INSPIRE Trial Finds Prebiotic Inulin Eases Knee Osteoarthritis Pain

MHRA Approves Leqselvi for Severe Alopecia Areata in Adults

Blood Test Using p‑Tau217 Predicts Dementia Risk in Women Up to 25 Years Before Symptoms

Apixaban Cuts Bleeding Versus Rivaroxaban in Venous Thrombosis, NEJM Head-to-Head Trial Finds

AI Tools Boost Breast Cancer Detection in NHS Studies, Cutting Reading Workloads

Viking Therapeutics Pushes VK2735 Through Pivotal Trials as Next Enrollment Milestone Nears

Vertex’s IgA Nephropathy Drug Hits Phase 3 Goals, FDA Filing Slated for March

C-Further Launches First Pediatric Cancer Programs, Taps MiNK for PRAME iNKT Therapy

uniQure Soars 36% After FDA Biologics Chief Vinay Prasad Announces April Exit

FDA Approves Sotyktu for Active Psoriatic Arthritis as First TYK2 Inhibitor

EMA Backs Single-Dose Acoziborole for Gambiense Sleeping Sickness Outside EU

EU Regulators Back First Combined COVID-19 and Flu mRNA Shot for Adults 50 and Over

FDA Maps New Paths for Rare-Disease Drug Evidence, Keeps Bar High